Please wait while the formulary information is being retrieved.
DICLOPR (DICLOFENAC SODIUM/METHYL SALICYLATE/MENTHOL)
1 %-30 %-10 % topical pack, gel and cream
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- Aspirin exacerbated respiratory disease
- Drug-induced hepatitis
- Gastrointestinal perforation
- Hepatic failure
- Post-operative from CABG surgery
- Pregnancy
- Severe hepatic disease
Contraindicated
- Abnormal hepatic function tests
- Acute myocardial infarction
- Alcoholism
- Burns
- Cerebrovascular accident
- Chronic heart failure
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Debilitation
- Disease of liver
- Duodenal ulcer
- Gastrointestinal hemorrhage
- Gastrointestinal ulcer
- Hypertension
- Increased cardiovascular event risk
- Increased risk of bleeding
- Peptic ulcer
- Skin ulcer
- Systemic mastocytosis
- Tobacco smoker
Severe
Moderate
- Anemia
- Asthma
- Edema
DICLOPR (DICLOFENAC SODIUM/METHYL SALICYLATE/MENTHOL)
- None
- Pruritus of skin
- Skin rash
- Stinging of skin
- Treatment site sequelae
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Drowsy
- Dry skin
- Dysgeusia
- Dyspepsia
- Edema
- Headache disorder
- Nausea
- Paresthesia
- Skin inflammation
- Skin irritation
- Skin ulcer
- Stinging of skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Anaphylaxis
- Anemia
- Body fluid retention
- Burns
- Cerebrovascular accident
- Diarrhea
- Dyspnea
- Exfoliative dermatitis
- Facial edema
- Gastric ulcer
- Gastrointestinal hemorrhage
- Gastrointestinal perforation
- Gastrointestinal ulcer
- Heart failure
- Hepatic failure
- Hepatic necrosis
- Hepatitis
- Hypersensitivity drug reaction
- Jaundice
- Periorbital edema
- Pharyngeal edema
- Platelet aggregation inhibition
- Renal papillary necrosis
- Skin ulcer
- Stevens-johnson syndrome
- Superficial skin ulcer
- Syncope
- Throat constriction
- Toxic epidermal necrolysis
- Urticaria
Less Severe
- Gastritis
- Hyperkinesis
- Hypertension
- Hypesthesia
- Localized edema
- Pruritus of skin
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Diclofenac (Select Routes)
Safety and efficacy in pediatrics have not been established.
Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 1 Day – 18 Years
- Safety and efficacy in pediatrics have not been established.
- 1 Day – 13 Years
- Safety and efficacy in pediatrics have not been established.
Salicylates (Topical)
Safety and efficacy in pediatrics have not been established.
Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 1 Day – 18 Years
- Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 1 Day – 13 Years
- Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
Diclofenac
- Severity Level:
1
- Additional Notes: Fda c before 30wks;premature closure of ductus arteriosus;early miscarriage risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Diclofenac (top)
Insufficient data available
Small amt of drug absorbed systemically;Risk of reye's syn w/oral salicylates
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
Methyl Salicylate (topical/nasal)
Insufficient data available
Small amt of drug absorbed systemically;Risk of reye's syn w/oral salicylates
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Small amt of drug absorbed systemically;Risk of reye's syn w/oral salicylates |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Diclofenac (topical)
Gastrointestinal-Caution with history of PUD or GI bleed. Renal-Monitor patients with renal impairment. Cardiovascular-May exacerbate pre-existing hypertension, CHF. Cardiovascular thrombotic event risk, including MI and stroke, increases with duration of use. Risk for reinfarction with minimal NSAID use post-MI. Contraindicated in the setting of CABG. Hepatic-Elevated hepatic transaminases may occur with chronic use.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | N | N | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- Nonsteroidal anti-inflammatory drugs (including diclofenac) may rarely increase the risk for a heart attack or stroke. This effect can happen at any time while using this drug but is more likely if you use it for a long time. The risk may be greater if you have heart disease or increased risk for heart disease (for example, due to smoking, family history of heart disease, or conditions such as high blood pressure or diabetes).<br /><br /> Do not use this drug right before or after heart bypass surgery (CABG). Also, this drug may rarely cause serious (rarely fatal) bleeding from the stomach or intestines. This side effect can occur without warning symptoms at any time while using diclofenac.<br /><br />Older adults may be at higher risk for this effect. (See also Precautions and Drug Interactions sections.) Stop using diclofenac and get medical help right away if you notice any of the following rare but very serious side effects: black/bloody stools, persistent stomach/abdominal pain, vomit that looks like coffee grounds, chest/jaw/left arm pain, shortness of breath, unusual sweating, confusion, weakness on one side of the body, sudden vision changes, slurred speech. Talk with your doctor or pharmacist about the benefits and risks of using this medication.
Formulary Reference Tool